US Stock MarketDetailed Quotes
IMAB I-Mab
- 0.947
- +0.007+0.74%
Close Nov 26 16:00 ET
- 0.934
- -0.013-1.37%
Post 20:01 ET
77.18MMarket Cap-1036P/E (TTM)
0.966High0.920Low120.74KVolume0.950Open0.940Pre Close114.34KTurnover0.25%Turnover RatioLossP/E (Static)81.50MShares2.53652wk High0.35P/B45.46MFloat Cap0.89952wk Low--Dividend TTM48.01MShs Float85.400Historical High--Div YieldTTM4.92%Amplitude0.899Historical Low0.946Avg Price1Lot Size
About I-Mab Company
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Rockville, MD.
Company Profile
SymbolIMAB
Company NameI-Mab
Listing DateJan 17, 2020
Issue Price14.00
Founded2016
CEODr. Xi-Yong Sean Fu
MarketNASDAQ
Employees220
Securities TypeDR
ADS Ratio10.0 : 23.0
Fiscal Year Ends12-31
Address2440 Research Boulevard,Suite 400
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-745-6330
Company Executives
- Name
- Position
- Salary
- Dr. Xi-Yong Sean Fu
- Interim Chief Executive Officer and Director
- --
- Joseph Skelton
- Chief Financial Officer
- --
- Dr. Phillip Dennis, M.D.
- Chief Medical Officer
- --
- Wei Fu
- Chairman of the Board
- --
- Lielie Zhang
- Independent Director
- --
- Chun Kwok Alan Au
- Independent Director
- --
- Chia-hung Conor Yang
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data